1 Introduction. The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of slowly progressing haematological malignancies primarily characterised by an overproduction of ...

BACKGROUND: Myeloproliferative neoplasms (MPN) are a group of chronic leukemias that are associated with pulmonary hypertension (PH), which has been associated with increased risk adverse outcomes.

With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a target enrichment panel to explore, using next-generation ...

In addition to the plenary presentation, Dr. Gill will also present results from the University of Hong Kong’s Phase 2 trial (NCT05731245) evaluating ropeginterferon alfa-2b in pre-fibrotic primary ...

As the Indiana Pacers qualify for their first NBA Finals since 2000, center Myles Turner has officially declared Tyrese Haliburton’s “overrated” label dead. “I’m so proud of Tyrese ...

WILMINGTON, Del., June 03, 2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025 ...

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms ...

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms. Business ... NQ=F Nasdaq 100 Jun 25 21,743.75-101.00 (-0.46%) BTC-USD Bitcoin USD ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Jun 3, 2025--PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms ...

JAK2 is a promising target for treating myeloproliferative neoplasms (MPNs). However, existing JAK2 inhibitors cannot fully cure these diseases and may induce resistance with prolonged use. Here, we ...

INCA035784, a Novel, Equipotent T Cell Redirecting Antibody for Patients with Myeloproliferative Neoplasms Carrying Different Types of Calreticulin Mutations (Session Title: Novel and Experimental ...

The FDA introduced Elsa, an artificial intelligence (AI) tool intended to enhance efficiency in clinical reviews and scientific evaluations.